For advanced HER2-positive breast cancer, intrinsic resistance refers to progression within 3 months after first-line treatment of metastatic disease, while acquired resistance refers to disease progression after 3 months of anti-HER2 administration. This evidence concerns the gene ERBB2 and breast cancer.